Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 5/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2008098 | 0.85 | GRM5 (0.44) | GRM5CYP11B1CYP11B2 | |
| SCHEMBL2013082 | 0.83 | GRM5 (0.54) | GRM5ARCYP1A2 | |
| SCHEMBL2015200 | 0.83 | GRM5 (0.42) | GRM5CYP1A2 | |
| SCHEMBL2007869 | 0.80 | GRM5 (0.50) | GRM5 | |
| SCHEMBL2014190 | 0.79 | GRM5 (0.50) | GRM5 | |
| SCHEMBL2010689 | 0.74 | GRM5 (0.49) | GRM5 | |
| SCHEMBL1023214 | 0.73 | GRM5 (0.60) | GRM5 | |
| SCHEMBL2013745 | 0.72 | GRM5 (0.53) | GRM5 | |
| SCHEMBL2009047 | 0.71 | GRM5 (0.52) | GRM5 | |
| SCHEMBL2008101 | 0.71 | GRM5 (0.65) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964620-B2 | Imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-06-21 | — | — | US | disclosed |
| EP-1831193-B1 | IMIDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2009-04-08 | — | — | EP | disclosed |
| US-20090018171-A1 | IMIDAZOLE DERIVATIVES | BUETTELMANN BERND | 2009-01-15 | — | — | US | disclosed |
| US-7452909-B2 | Imidazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2008-11-18 | — | — | US | disclosed |
| EP-1831193-A1 | IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-09-12 | — | — | EP | disclosed |
| WO-2005023795-A1 | IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-17 | — | — | WO | disclosed |
| US-20050054686-A1 | Imidazole derivatives | HOFFMANN-LA ROCHE INC. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054686-A1 | Imidazole derivatives | CHRM2, CHRM1, ARG1 | GRM5 758/4885AR 3345/4885ALDH1A1 1611/4885 |
| US-20090018171-A1 | IMIDAZOLE DERIVATIVES | CHRM2, CHRM1, ARG1 | GRM5 758/4885AR 3345/4885ALDH1A1 1611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.